GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Cyclically Adjusted PB Ratio

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Cyclically Adjusted PB Ratio : (As of Jun. 08, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pathfinder Cell Therapy Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Cyclically Adjusted PB Ratio Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio falls into.



Pathfinder Cell Therapy Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pathfinder Cell Therapy's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2015 is calculated as:

For example, Pathfinder Cell Therapy's adjusted Book Value per Share data for the three months ended in Sep. 2015 was:

Adj_Book=Book Value per Share/CPI of Sep. 2015 (Change)*Current CPI (Sep. 2015)
=-0.01/100.3915*100.3915
=-0.010

Current CPI (Sep. 2015) = 100.3915.

Pathfinder Cell Therapy Quarterly Data

Book Value per Share CPI Adj_Book
200512 0.002 83.032 0.002
200603 -0.006 84.298 -0.007
200606 0.054 85.606 0.063
200609 0.045 85.606 0.053
200612 0.040 85.142 0.047
200703 0.031 86.640 0.036
200706 0.021 87.906 0.024
200709 0.039 87.964 0.045
200712 0.032 88.616 0.036
200803 0.018 90.090 0.020
200806 0.009 92.320 0.010
200809 0.038 92.307 0.041
200812 0.029 88.697 0.033
200903 0.021 89.744 0.023
200906 0.011 91.003 0.012
200909 0.009 91.120 0.010
200912 0.008 91.111 0.009
201003 0.006 91.821 0.007
201006 0.001 91.962 0.001
201009 -0.004 92.162 -0.004
201012 -0.010 92.474 -0.011
201103 -0.012 94.283 -0.013
201106 -0.015 95.235 -0.016
201109 -0.001 95.727 -0.001
201112 -0.001 95.213 -0.001
201203 -0.002 96.783 -0.002
201206 -0.003 96.819 -0.003
201209 -0.004 97.633 -0.004
201212 -0.004 96.871 -0.004
201303 -0.005 98.209 -0.005
201306 -0.006 98.518 -0.006
201309 -0.006 98.790 -0.006
201312 -0.007 98.326 -0.007
201403 -0.008 99.695 -0.008
201406 -0.008 100.560 -0.008
201409 -0.008 100.428 -0.008
201412 -0.009 99.070 -0.009
201503 -0.009 99.621 -0.009
201506 -0.010 100.684 -0.010
201509 -0.010 100.392 -0.010

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pathfinder Cell Therapy  (OTCPK:PFND) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pathfinder Cell Therapy Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines